在各种癌症中对纤维细胞生长因子受体路径的分子向
Khine S Shan1, Shivani Dalal1, Nyein Nyein Thaw Dar1
1Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA.
International journal of molecular sciences
|January 23, 2024
概括
纤维细胞生长因子受体 (FGFR) 的改变驱动瘤的发展. 本综述涵盖了FGFR向剂,它们的临床疗效,以及克服耐药性的未来方向.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 纤维细胞生长因子受体 (FGFRs) 是细胞生长和存活的关键调节者.
- FGFR的变化 (放大,融合,突变) 激活下游信号,促进瘤的发展.
- FGFRs与胆管癌和泌尿器癌等癌症有关.
研究的目的:
- 审查使用FGFR向剂的临床经验.
- 总结FGFR向治疗的当前发展情况.
- 讨论FGFR向治疗的未来策略.
主要方法:
- 临床试验和临床前研究的文献综述.
- 对FGFR抑制剂,配体陷,抗体和抗体-药物合物的数据分析.
- 综合有关疗效,毒性和耐药性机制的信息.
主要成果:
- 四种FGFR抑制剂被FDA批准用于特定的癌症.
- 目前正在开发针对FGFR通路的各种药物.
- 当前的药物表现出不同的反应,毒性和获得的耐药性.
结论:
- 向FGFR变化是一种经过验证的治疗策略.
- 需要进一步的研究来优化针对FGFR的治疗方法.
- 克服阻力和提高响应率是关键的未来方向.
关键词:
联邦政府财政基金.在FGFR中,FGFR是FGFR.纤维细胞生长因子的成长因子纤维细胞生长因子受体基因组特征分析 (genomic profiling) 是一种基因组特征.个性化医疗是个性化的医疗.有针对性的治疗.更多相关视频
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K


